How much did AnGes achieve in EBIT for the current year?
In the current year, AnGes has achieved an EBIT of -11.97 B JPY.
AnGes EBIT 2024
AnGes EBIT
-11.97 B JPY
Ticker
4563.T
ISIN
JP3127700007
WKN
779518
In 2024, AnGes's EBIT was -11.97 B JPY, a -26.62% increase from the -16.31 B JPY EBIT recorded in the previous year.
The AnGes EBIT history
| YEAR | EBIT (undefined JPY) |
|---|---|
| 2023 | - |
| 2022 | - |
| 2021 | - |
| 2020 | - |
| 2019 | - |
| 2018 | - |
| 2017 | - |
| 2016 | - |
| 2015 | - |
| 2014 | - |
| 2013 | - |
| 2012 | - |
| 2011 | - |
| 2010 | - |
| 2009 | - |
| 2008 | - |
| 2007 | - |
| 2006 | - |
| 2005 | - |
| 2004 | - |
AnGes Revenue, EBIT, Net Income JP3127700007 · 779518
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into AnGes, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by AnGes from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects AnGes’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of AnGes. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into AnGes’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing AnGes’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on AnGes’s growth potential.
AnGes Revenue, EBIT and net profit per share
| Date | AnGes Revenue | AnGes EBIT | AnGes Net Income |
|---|---|---|---|
| 2023 | 152.99 M undefined | -11.97 B undefined | -7.44 B undefined |
| 2022 | 67.06 M undefined | -16.31 B undefined | -14.71 B undefined |
| 2021 | 64.15 M undefined | -15.63 B undefined | -13.68 B undefined |
| 2020 | 40 M undefined | -5.6 B undefined | -4.21 B undefined |
| 2019 | 326.76 M undefined | -3.27 B undefined | -3.75 B undefined |
| 2018 | 610.05 M undefined | -3.07 B undefined | -3 B undefined |
| 2017 | 365.18 M undefined | -3.29 B undefined | -3.76 B undefined |
| 2016 | 514.27 M undefined | -4.76 B undefined | -4.78 B undefined |
| 2015 | 430.15 M undefined | -4.17 B undefined | -4.14 B undefined |
| 2014 | 909.9 M undefined | -2.27 B undefined | -2.37 B undefined |
| 2013 | 491.3 M undefined | -1.36 B undefined | -1.41 B undefined |
| 2012 | 444.5 M undefined | -1.79 B undefined | -1.71 B undefined |
| 2011 | 243.4 M undefined | -2.1 B undefined | -1.82 B undefined |
| 2010 | 286.9 M undefined | -2.01 B undefined | -1.97 B undefined |
| 2009 | 585.7 M undefined | -2.61 B undefined | -2.92 B undefined |
| 2008 | 951.1 M undefined | -2.76 B undefined | -3.53 B undefined |
| 2007 | 1.72 B undefined | -2.04 B undefined | -1.73 B undefined |
| 2006 | 2.91 B undefined | -1.52 B undefined | -1.11 B undefined |
| 2005 | 2.43 B undefined | -1.97 B undefined | -1.91 B undefined |
| 2004 | 2.7 B undefined | -1.56 B undefined | -1.54 B undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2004 | 2.7 B JPY | -1.56 B JPY | -1.54 B JPY |
| 2005 | 2.43 B JPY | -1.97 B JPY | -1.91 B JPY |
| 2006 | 2.91 B JPY | -1.52 B JPY | -1.11 B JPY |
| 2007 | 1.72 B JPY | -2.04 B JPY | -1.73 B JPY |
| 2008 | 951.1 M JPY | -2.76 B JPY | -3.53 B JPY |
| 2009 | 585.7 M JPY | -2.61 B JPY | -2.92 B JPY |
| 2010 | 286.9 M JPY | -2.01 B JPY | -1.97 B JPY |
| 2011 | 243.4 M JPY | -2.1 B JPY | -1.82 B JPY |
| 2012 | 444.5 M JPY | -1.79 B JPY | -1.71 B JPY |
| 2013 | 491.3 M JPY | -1.36 B JPY | -1.41 B JPY |
| 2014 | 909.9 M JPY | -2.27 B JPY | -2.37 B JPY |
| 2015 | 430.15 M JPY | -4.17 B JPY | -4.14 B JPY |
| 2016 | 514.27 M JPY | -4.76 B JPY | -4.78 B JPY |
| 2017 | 365.18 M JPY | -3.29 B JPY | -3.76 B JPY |
| 2018 | 610.05 M JPY | -3.07 B JPY | -3 B JPY |
| 2019 | 326.76 M JPY | -3.27 B JPY | -3.75 B JPY |
| 2020 | 40 M JPY | -5.6 B JPY | -4.21 B JPY |
| 2021 | 64.15 M JPY | -15.63 B JPY | -13.68 B JPY |
| 2022 | 67.06 M JPY | -16.31 B JPY | -14.71 B JPY |
| 2023 | 152.99 M JPY | -11.97 B JPY | -7.44 B JPY |
AnGes stock margins JP3127700007 · 779518
The AnGes margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AnGes. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AnGes.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the AnGes's sales revenue. A higher gross margin percentage indicates that the AnGes retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the AnGes's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the AnGes's total revenue generated. When comparing the revenue margin year over year, investors can gauge the AnGes's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the AnGes. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the AnGes's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
AnGes Margin History
| AnGes Gross margin | AnGes Profit margin | AnGes EBIT margin | AnGes Profit margin |
|---|---|---|---|
| 2023 | 12.71 % | -7,822.67 % | -4,861.66 % |
| 2022 | -40.01 % | -24,320.76 % | -21,942.37 % |
| 2021 | 11.58 % | -24,358.89 % | -21,318.8 % |
| 2020 | 42.45 % | -13,999.18 % | -10,524.3 % |
| 2019 | 73.31 % | -1,000.74 % | -1,147.89 % |
| 2018 | 69.15 % | -502.46 % | -491.21 % |
| 2017 | 51.24 % | -900.56 % | -1,030.91 % |
| 2016 | 66.07 % | -926.24 % | -928.85 % |
| 2015 | 58.22 % | -969.88 % | -963.22 % |
| 2014 | 83.4 % | -249.91 % | -260.38 % |
| 2013 | 73.3 % | -277.47 % | -286.93 % |
| 2012 | 70.93 % | -401.66 % | -384.34 % |
| 2011 | 66.64 % | -863.06 % | -745.73 % |
| 2010 | 71.14 % | -700.7 % | -685.67 % |
| 2009 | 88.36 % | -445.77 % | -498.79 % |
| 2008 | 94.82 % | -289.81 % | -371.61 % |
| 2007 | 100 % | -118.58 % | -100.49 % |
| 2006 | 12.71 % | -52.3 % | -38.28 % |
| 2005 | 12.71 % | -81.09 % | -78.39 % |
| 2004 | 12.71 % | -57.9 % | -57.17 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2004 | 12.71 % | -57.9 % | -57.17 % |
| 2005 | 12.71 % | -81.09 % | -78.39 % |
| 2006 | 12.71 % | -52.3 % | -38.28 % |
| 2007 | 100 % | -118.58 % | -100.49 % |
| 2008 | 94.82 % | -289.81 % | -371.61 % |
| 2009 | 88.36 % | -445.77 % | -498.79 % |
| 2010 | 71.14 % | -700.7 % | -685.67 % |
| 2011 | 66.64 % | -863.06 % | -745.73 % |
| 2012 | 70.93 % | -401.66 % | -384.34 % |
| 2013 | 73.3 % | -277.47 % | -286.93 % |
| 2014 | 83.4 % | -249.91 % | -260.38 % |
| 2015 | 58.22 % | -969.88 % | -963.22 % |
| 2016 | 66.07 % | -926.24 % | -928.85 % |
| 2017 | 51.24 % | -900.56 % | -1,030.91 % |
| 2018 | 69.15 % | -502.46 % | -491.21 % |
| 2019 | 73.31 % | -1,000.74 % | -1,147.89 % |
| 2020 | 42.45 % | -13,999.18 % | -10,524.3 % |
| 2021 | 11.58 % | -24,358.89 % | -21,318.8 % |
| 2022 | -40.01 % | -24,320.76 % | -21,942.37 % |
| 2023 | 12.71 % | -7,822.67 % | -4,861.66 % |
AnGes Aktienanalyse
What does AnGes do?
AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing AnGes's EBIT
AnGes's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of AnGes's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
AnGes's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in AnGes’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about AnGes stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company AnGes.
How has the EBIT of AnGes developed in recent years?
The EBIT of AnGes has increased by -26.624% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company AnGes?
The EBIT of AnGes is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does AnGes pay?
Over the past 12 months, AnGes paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnGes is expected to pay a dividend of 0 JPY.
What is the dividend yield of AnGes?
The current dividend yield of AnGes is .
When does AnGes pay dividends?
AnGes pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnGes?
AnGes paid dividends every year for the past 0 years.
What is the dividend of AnGes?
For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnGes located?
AnGes is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnGes kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnGes from 11/30/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 11/30/2024.
When did AnGes pay the last dividend?
The last dividend was paid out on 11/30/2024.
What was the dividend of AnGes in the year 2023?
In the year 2023, AnGes distributed 0 JPY as dividends.
In which currency does AnGes pay out the dividend?
The dividends of AnGes are distributed in JPY.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnGes
Our stock analysis for AnGes Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnGes Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
